Most Read News

Beige, an investment firm, sold 58,17,874 equity shares in the pharmaceutical company at an average price of ₹2,124.71 per share.

CEO Rajiv Sabharwal stated that the funds were raised as part of the company's $750-million external commercial borrowing (ECB) scheme, in accordance with Reserve Bank of India requirements.

On the Experience side, synergies haven’t played out as that is largely discretionary spend. Real estate consolidation is ongoing, benefits of which should be visible over the next few quarters.

Maruti Suzuki assured affected vehicle owners of free replacement of the faulty part through authorized dealer workshops.

IndiGo’s advantages range from its cost leadership, efficient operations/fleet strategy and its unparalleled network. IndiGo plans to expand its fleet from current 366 (incl. 70+ grounded) to 600+ aircraft by 2030. Analysts of IIFL Capital Services expect Indigo to maintain its leadership in domestic traffic (current mkt share 62%). In addition, IndiGo is growing its international ops at a fast clip, with 33 international destinations and strategic partnerships with 8 global carriers. Induction of XLRs would increase IndiGo’s flying range to mid-long haul markets.

Fuel costs have been stable over M9FY24. For Q4FY24, analysts of IIFL Capital Services expect gas costs to have come down by 6-7% QoQ; however, given the pressure on volumes, they gather that discounts/incentives have increased.

In terms of sectoral performance, the banking and Information Technology indices witnessed a decline of 0.5% each, while the capital goods, realty, oil & gas, and metal sectors experienced gains ranging from 0.5 to 1%.

Although Germany and France are potential locations for the hub, no final decision has been made regarding the warehouse's precise location, Gopal mentioned.

The minimum bid lot comprises 70 equity shares, with subsequent multiples of 70, requiring a minimum investment of ₹14,000 at the lower price band.

In a press release, the pharmaceutical business stated that the USFDA has tentatively approved Zydus Lifesciences, together with its subsidiaries and affiliates, to manufacture and sell Edaravone Injection in a single-dose vial.